Coronavirus COVID-19 Daily Update 8th April 2020

Samantha Goh

8th Apr 2020

Coronavirus COVID-19 Daily Update 8th April 2020

This update will be published daily at 12pm GMT and aims to provide clinicians and the public with an overview of the latest data, guidelines, key publications and policy around COVID-19, with links to essential resources and information.

If you are a healthcare professional, please join the discussion on these latest COVID-19 cases on MedShr:

Please post any COVID-19 cases, images or learning points from your clinical practice on MedShr - share key knowledge and experience with a global network of doctors to help improve patient care. Include #COVID19 in your case title.

Please email COVID@medshr.net if you have any data, publications or information you would like to share.

Global Impact of COVID-19 to Date

As of 8th April 09:00 (GMT)

Source: Johns Hopkins University & Medicine

COVID-19 Cumulative Global Cases

As of 8th April 09:00 (GMT)

Source: World Health Organisation

COVID-19 Global Active Cases Map

As of 8th April 09:00 GMT

Source: Johns Hopkins University & Medicine

Total UK COVID-19 Cases

As of 7th April

NB: Public Health England has now moved to a different reporting time for UK COVID-19 fatalities, as family consent is now needed to release mortality statistics. Hence the reported figures may not actually be the deaths that have taken place over the past 24 hours, meaning caution needs to be exercised when comparing figures from one day to the next.

Source: Public Health England

COVID-19 Cumulative UK Cases

As of 7th April

Source: Public Health England

COVID-19 Daily UK Cases

As of 7th April

Source: Public Health England

Coronavirus Infection trajectories

As of 8th April 2020

Source: informationisbeautiful

Source: informationisbeautiful

COVID-19 Key Data

Source: informationisbeautiful

Source: informationisbeautiful

Source: J P Morgan

Source: J P Morgan

Excerpt from J P Morgan: Vaccine and anti-viral update; the Chloroquine controversy; Convalescent plasma (Last update 4th April 2020)

Critique of Study by Gautret el al, March 2020: Hydroxychloroquine and Azithromycin as a treatment of COVID-19: preliminary results of an open-label non-randomized clinical trial

non-randomized trial with only 36 patients, and had no discussion of outcomes
excluded 6 recipients that were not discussed, some of whom of required ventilation and/or died
started out with higher viral loads in the control group than in the infected patients, which could explain why the control group showed higher infected rates at the conclusion of the study
imputed more than 1/3 of the control group virus tests rather than measuring them
sourced its treatment group (unlike the control group) from a single medical center

Source: J P Morgan